专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09376495B2 Deimmunized serum-binding domains and their use in extending serum half-life 有权
标题翻译：去免疫的血清结合结构域及其在延长血清半衰期中的应用
公开(公告)号：US09376495B2
公开(公告)日：2016-06-28
申请号：US14118516
申请日：2012-05-16
申请人： Ezio Bonvini , Bhaswati Barat , Ling Huang , Leslie S. Johnson
发明人： Ezio Bonvini , Bhaswati Barat , Ling Huang , Leslie S. Johnson
IPC分类号： A61K39/00 , C07K16/28 , C07K16/32 , C07K16/44
CPC分类号： C07K16/32 , C07K14/315 , C07K16/2803 , C07K16/2809 , C07K16/283 , C07K16/2851 , C07K16/44 , C07K2317/24 , C07K2317/31 , C07K2317/567 , C07K2317/62 , C07K2317/624 , C07K2317/626 , C07K2317/73 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2319/31 , C07K2319/32 , C07K2319/73
摘要： The present invention is directed to a polypeptide (for example, an antigen-binding molecule) that comprises a polypeptide portion of a deimmunized serum-binding protein capable of binding to said serum protein. The presence of the serum-binding protein extends the serum half-life of the polypeptide, relative to the serum half-life of the polypeptide if lacking the polypeptide portion of the deimmunized serum-binding protein. The invention also pertains to methods and uses that employ such molecules.
摘要翻译：本发明涉及包含能够结合所述血清蛋白的解除免疫的血清结合蛋白的多肽部分的多肽（例如，抗原结合分子）。如果缺乏去免疫的血清结合蛋白的多肽部分，则血清结合蛋白的存在相对于多肽的血清半衰期延长了多肽的血清半衰期。本发明还涉及使用这种分子的方法和用途。

2. 发明申请

US20150023964A1 FcgammaRIIB-Specific Antibodies and Methods of Use Thereof 审中-公开
标题翻译： FcgammaRIIB特异性抗体及其使用方法
公开(公告)号：US20150023964A1
公开(公告)日：2015-01-22
申请号：US14331360
申请日：2014-07-15
申请人： Leslie S. Johnson , Ling Huang , Robyn Gerena
发明人： Leslie S. Johnson , Ling Huang , Robyn Gerena
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395
CPC分类号： C07K16/283 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/732 , C07K2317/92
摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than the antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
摘要翻译：本发明涉及以比抗体或其片段更大的亲和力结合FcγRIIA，特别是人FcγRIIA的FcγRIIB特别是人FcγRIIB特异性结合的抗体或其片段。本发明还提供抗FcγRIIB抗体或其抗原结合片段作为治疗，预防，治疗或改善癌症，优选B细胞恶性肿瘤，特别是B细胞恶性肿瘤的单一药物治疗的用途细胞性慢性淋巴细胞白血病或非霍奇金淋巴瘤，自身免疫性疾病，炎症性疾病，IgE介导的过敏性疾病或其一种或多种症状。本发明提供了通过施用本发明的抗体来增强治疗性抗体的效应功能来增强治疗性抗体的治疗效果的方法。本发明还提供了通过施用本发明的抗体来增强疫苗组合物的功效的方法。

3. 发明授权

US08216579B2 Humanized FcγRIIB-specific antibodies and methods of use thereof 有权
标题翻译：人源化FcγRIIB特异性抗体及其使用方法
公开(公告)号：US08216579B2
公开(公告)日：2012-07-10
申请号：US12785117
申请日：2010-05-21
申请人： Leslie S. Johnson , Ling Huang
发明人： Leslie S. Johnson , Ling Huang
IPC分类号： A61K39/395
CPC分类号： A61K39/39 , A61K2039/505 , A61K2039/55516 , C07K16/283 , C07K2317/24 , C07K2317/34 , C07K2317/52 , G01N33/564 , G01N33/6893 , G01N2800/24
摘要： The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.
摘要翻译：本发明涉及以比所述抗体结合FcγRIIA更大的亲和力结合人FcγRIIB的人源化FcγRIIB抗体，其片段和变体。本发明包括本发明的人源化抗体用于治疗与Fc受体介导的信号传导的平衡丧失有关的任何疾病（例如癌症，自身免疫性和炎症性疾病）的用途。本发明提供了通过施用本发明的人源化抗体来增强治疗性抗体的治疗效果以增强治疗性抗体的效应子功能的方法。本发明还提供了通过施用本发明的人源化抗体来增强疫苗组合物的功效的方法。本发明包括治疗自身免疫性疾病的方法和用于消除表达FcγRIIB的癌细胞的方法。

4. 发明申请

US20110152504A1 CD16A Binding Proteins and Use for the Treatment of Immune Disorders 审中-公开
标题翻译： CD16A结合蛋白和用于治疗免疫疾病的用途
公开(公告)号：US20110152504A1
公开(公告)日：2011-06-23
申请号：US12904554
申请日：2010-10-14
申请人： Leslie S. Johnson , Ling Huang , Hua Li , Nadine Tuaillon
发明人： Leslie S. Johnson , Ling Huang , Hua Li , Nadine Tuaillon
IPC分类号： C07K16/28
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/24 , C07K2317/41 , C07K2317/732
摘要： CD 16A binding proteins useful for the reduction of a deleterious immune response asre described. In one aspect, humanized anti-cd16A antibodies, optionally lacking effector function, are used for the treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimme hemolytic anemia.
摘要翻译： CD 16A结合蛋白可用于减少有害免疫反应。在一个方面，任选缺乏效应子功能的人源化抗-CD16A抗体用于治疗免疫疾病如特发性血小板减少性紫癜和自身免疫性溶血性贫血。

5. 发明授权

US09889197B2 Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin 有权
公开(公告)号：US09889197B2
公开(公告)日：2018-02-13
申请号：US13811883
申请日：2011-07-29
申请人： Leslie S. Johnson , Ling Huang , Godfrey Jonah Anderson Rainey
发明人： Leslie S. Johnson , Ling Huang , Godfrey Jonah Anderson Rainey
IPC分类号： A61K39/395 , C07K16/30 , C07K16/28 , A61K38/16 , C07K14/315 , C07K16/32 , C07K16/44
CPC分类号： A61K39/39558 , A61K38/164 , C07K14/315 , C07K16/2803 , C07K16/2809 , C07K16/283 , C07K16/2851 , C07K16/32 , C07K16/44 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/52 , C07K2317/626 , C07K2317/64 , C07K2317/73 , C07K2317/92 , C07K2317/94 , C07K2319/31 , C07K2319/70
摘要： Diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers are disclosed. The diabody molecules comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as disulfide bonding of cysteine residues located within each polypeptide chain. The diabody molecules may further comprise an Fc region, which allows antibody-like functionality to be engineered into the molecule.

6. 发明授权

US09296816B2 Covalent diabodies and uses thereof 有权
标题翻译：共价双抗体及其用途
公开(公告)号：US09296816B2
公开(公告)日：2016-03-29
申请号：US11409339
申请日：2006-04-17
申请人： Leslie S. Johnson , Ling Huang
发明人： Leslie S. Johnson , Ling Huang
IPC分类号： C07K16/28 , A61K39/00
CPC分类号： C07K16/283 , A61K2039/505 , C07K16/08 , C07K16/12 , C07K16/30 , C07K16/44 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/53 , C07K2317/622 , C07K2317/626
摘要： The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.
摘要翻译：本发明涉及双抗体分子及其在治疗各种疾病和病症（包括免疫学疾病，感染性疾病，中毒和癌症）中的用途。本发明的双抗体分子包含两个缔合以形成至少两个表位结合位点的多肽链，其可识别相同或不同抗原上相同或不同的表位。另外，抗原可以来自相同或不同的分子。双抗体分子的单个多肽链可以通过非肽键共价键共价结合，例如但不限于位于每个多肽链内的半胱氨酸残基的二硫键。在具体实施方案中，本发明的双抗体分子还包含Fc区，其允许抗体样功能被改造成分子。

7. 发明授权

US09284375B2 Covalent diabodies and uses thereof 有权
公开(公告)号：US09284375B2
公开(公告)日：2016-03-15
申请号：US12641095
申请日：2009-12-17
申请人： Leslie S. Johnson , Ling Huang
发明人： Leslie S. Johnson , Ling Huang
IPC分类号： C07K16/00 , C07K16/28
CPC分类号： C07K16/283 , C07K2317/34 , C07K2317/52 , C07K2317/626 , C07K2317/73
摘要： The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.

8. 发明授权

US09150656B2 Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof 有权
标题翻译：与B7-H3反应的抗体，其免疫活性片段及其用途
公开(公告)号：US09150656B2
公开(公告)日：2015-10-06
申请号：US13581340
申请日：2011-03-01
申请人： Leslie S. Johnson , Paul A. Moore , Ling Huang , Deryk T. Loo , Francine Zhifen Chen
发明人： Leslie S. Johnson , Paul A. Moore , Ling Huang , Deryk T. Loo , Francine Zhifen Chen
IPC分类号： A61K38/00 , C07K16/30 , C07K16/28 , A61K39/395 , A61K45/06 , C07K16/44 , G01N33/68 , A61K39/00
CPC分类号： C07K16/30 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/2803 , C07K16/2827 , C07K16/2896 , C07K16/3076 , C07K16/3092 , C07K16/44 , C07K16/468 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/6893
摘要： The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
摘要翻译：本发明涉及对哺乳动物，特别是人B7-H3受体及其用途，特别是治疗癌症和炎症的免疫反应性的抗体及其片段。因此，本发明特别涉及人源化的B7-H3-反应性抗体及其能够介导，更优选增强针对与多种人类癌症相关的癌细胞的免疫系统的活化的免疫反应性片段。

9. 发明申请

US20130149236A1 Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof 有权
公开(公告)号：US20130149236A1
公开(公告)日：2013-06-13
申请号：US13581340
申请日：2011-03-01
申请人： Leslie S. Johnson , Paul A. Moore , Ling Huang , Deryk T. Loo , Francine Zhifen Chen
发明人： Leslie S. Johnson , Paul A. Moore , Ling Huang , Deryk T. Loo , Francine Zhifen Chen
IPC分类号： C07K16/30 , C07K16/28 , A61K39/395 , C07K16/44 , A61K45/06 , G01N33/68
CPC分类号： C07K16/30 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/2803 , C07K16/2827 , C07K16/2896 , C07K16/3076 , C07K16/3092 , C07K16/44 , C07K16/468 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/6893
摘要： The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.

10. 发明申请

US20110117089A1 BCR-Complex-Specific Antibodies And Methods Of Using Same 有权
标题翻译： BCR-复合物特异性抗体及其使用方法
公开(公告)号：US20110117089A1
公开(公告)日：2011-05-19
申请号：US12933882
申请日：2009-03-25
申请人： Leslie S. Johnson , Ling Huang
发明人： Leslie S. Johnson , Ling Huang
IPC分类号： A61K39/395 , C07K16/28 , C07H21/00 , A61P35/00 , A61P37/02 , A61P3/10 , A61P37/06
CPC分类号： C07K16/28 , C07K16/2803 , C07K2317/24 , C07K2317/56
摘要： This invention relates to chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
摘要翻译：本发明涉及特异性结合BCR复合物的嵌合和人源化抗体，特别是涉及BCR复合物的嵌合和人源化抗体。本发明还涉及将抗体及其组合物用于诊断，预后和治疗诸如癌症，自身免疫性疾病，炎症性疾病和感染性疾病的疾病的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式